CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced its financial results and business highlights for the first quarter ended March 31, 2012. The company has also announced that its New Drug Application (NDA) for lomitapide for the treatment of the adult Homozygous Familial Hypercholesterolemia (HoFH) population was accepted for review by the FDA. In March, the Company previously announced that the European Medicines Agency (EMA) had accepted for review the Marketing Authorization Application (MAA) for lomitapide. Aegerion is seeking approval of lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies to reduce cholesterol in patients with HoFH.
